Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Retinitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Retinitis is inflammation of the retina in the eye, which can permanently damage the retina and lead to blindness. The retina is the part of your eye that is also known as the "sensing tissue." Retinitis may be caused by a number of different infectious agents. Retinitis, also called Retinitis pigmentosa, has a prevalence of one in every 2,500–7,000 people. This condition is one of the leading causes that leads to blindness in patients in the age range of 20–60 years old.
Method and apparatus for improving both lateral and axial resolution in ophthalmoscopy
The invention provides a method of optical imaging comprising providing a sample to be imaged, measuring and correcting aberrations associated with the sample using adaptive optics, and imaging the sample by optical coherence tomography. The method can be used to image the fundus of a human eye to provide diagnostic information about retinal pathologies such as macular degeneration, retinitis pigmentosa, glaucoma, or diabetic retinopathy. The invention further provides an apparatus comprising an adaptive optics subsystem and a two-dimensional optical coherence tomography subsystem.
Owner:UNIVERSITY OF ROCHESTER
Normal Tissue Toxicity Reducing Microbeam-Broadbeam Radiotherapy, Skin's Radio-Response Immunotherapy and Mutated Molecular Apheresis Combined Cancer Treatments
InactiveUS20180154183A1Improve treatment outcomesIncreased toxicityOther blood circulation devicesHaemofiltrationAbnormal tissue growthGamma ray
Normal tissue complications limit curative broadbeam radiotherapy to tumors including lung cancer. Radiation retinitis causing blindness limits quality of life and long term survival for patients with ocular melanoma. This invention pertains to alternative, normal tissue sparing 100 to 1,000 Gy microbeam radiations with least normal tissue complications and concomitant radio-immunotherapy by innate immune response of epidermis and dermis to low dose radiation with 50 kV X-rays. Total body skin radiation with former airport passenger screening machines with 50 kV X-ray is disclosed. Microbeams are generated without contaminating scatter and neutron radiations from collinear gamma ray and electron beam produced by inverse Compton interaction with high energy laser and electron beam and from proton and carbon ion beams in tissue equivalent cylindrical collimators. Extracorporeal immunotherapy and chemotherapy and apheresis of mutated subcellular particles released into circulation in response to cancer-therapies are by clinical continuous flow ultracentrifugation combined chromatography.
Owner:SAHADEVAN VELAYUDHAN
Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
InactiveUS6899877B2Inhibiting retinal tearReducing and preventing effectSenses disorderEye implantsUrokinase Plasminogen ActivatorVascular proliferation
A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.
Owner:MINU
Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases
InactiveUS20050096282A1Shorten the progressDecreasing the amount of mRNA encodingSenses disorderVirusesRetinalVirus
Disclosed are ribozymes, as well as compositions, vectors, virus particles, host cells, and therapeutic kits comprising them useful in the treatment of diseases of the eye, including retinopathy and macular degeneration, and the amelioration of symptoms of such diseases including loss of vision, retinitis, and blindness.
Owner:FLORIDA RES FOUND UNIV OF
Substituted quinazolines and analogs and the use thereof
The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.
Owner:PURDUE PHARMA LP
Methods and compositions for gene delivery to on bipolar cells
InactiveUS20170007720A1Overcome limitationsImprove efficiencyVectorsPeptide/protein ingredientsGene deliveryRetinitis pigmentosa
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for intravitreal delivery of therapeutic gene constructs to retinal neuron cells, and specifically to ON bipolar cells, of the mammalian eye, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and / or in vivo applications including the treatment of retinitis pigmentosa, melanoma-associated retinopathy, and congenital stationary night blindness.
Owner:THE UNIV OF BRITISH COLUMBIA +1
Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
InactiveUS20130137642A1Reduce and prevent of and cell viabilityReduce cell viabilitySenses disorderDipeptide ingredientsRetinitis pigmentosaRetinal pigment epithelial cell
Provided are methods and compositions for maintaining the viability of photoreceptor cells and / or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and / or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
Owner:VAVVAS DEMETRIOS +3
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
ActiveUS20140121197A1Useful in treatmentBiocideOrganic chemistryHL - Hearing lossRetinitis pigmentosa
Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.
Owner:USHER III INITIATIVE
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER LAMBERT CO LLC
Use of crispr/cas9 as in vivo gene therapy to generate targeted genomic disruptions in genes bearing dominant mutations for retinitis pigmentosa
PendingUS20160324987A1Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsDiseaseIn vivo
Described herein are methods and compositions for genomic editing. Clustered regularly interspaced short palindromic (CRISPR) allows for highly selective targeting and alteration of genetic loci. Here, the Inventors demonstrate CRISPR as capable of being used in living animals to prophylactically prevent a genetic disease from manifesting. Targeting and disruption of mutated rhodopsin gene prevents progression of retinitis pigmentosa in the retinal cells of a transgenic rat model. Such techniques allow for treatment methods in subjects with dominant genetic mutations, often associated with lack of a gene product, or a toxic gene product. The described technology effectively abrogates deleterious effects due to the presence of a mutated gene copy allowing the normal function of the wild-type protein to prevent cell and vision loss. The efficacy of these in vivo mechanisms are widely extensible to similar dominant negative gene mutations causing disease, or other types of genetic disease.
Owner:CEDARS SINAI MEDICAL CENT
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER-LAMBERT CO
Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation
InactiveCN102600386AGood treatment effectNo drug resistanceSenses disorderPlant ingredientsSide effectTreatment effect
The invention discloses a Chinese herba preparation for treating eye inflammation and a preparation method of the traditional Chinese preparation. The Chinese herba preparation is prepared by cassia occidentalis, concha haliotidis, bat dung, centipeda minima, emilia sonchifolia, pipewort, feather cockscomb seeds, wild chrysanthemum flower, rehmannia glutinosa, Chinese yam, pulp of dogwood fruit, rhizoma alismatis, tuckahoe, cortex moutan radicis, wolfberry, cape jasmine, mother of pearl, scouring rush, bamboo shavings, caltrop and roots of hairy asiabell. The Chinese herba preparation is a Chinese medicinal herb preparation, and has a good treatment effect for acute or chronic conjunctivitis, central retinitis and optic neuritis, and after the Chinese herba preparation is clinically used for treating more than totally 100 cases of eye diseases of more than 600 patients for more than ten years, effective rate can be higher than 90%. In addition, according to clinical verifications, the Chinese herba preparation does not cause drug resistance and does not have toxic and side effects.
Owner:龙步明
Troxerutin powder injection
InactiveCN1586467AImprove stabilityQuality assurancePowder deliveryOrganic active ingredientsHydrolysateFreeze-drying
The troxerutin powder for injection includes troxerutin 2-100 wt% and excipient 0-98 wt%, and the excipient is one of mannitol, lactose, glycine, sorbic alcohol, low molecular weight dextran, glucose, cane sugar and hydrolysate gel. It is bacteria-free powder or bacteria-free freeze dried produce. The present invention is used in treating ischemic cerebral vascular diseases, central retinitis, arteriosclerosis, thrombotic phlebitis, varicosity, etc. and has the advantages of stability, fast dissolution in water and high safety.
Owner:广东阳江制药厂有限公司
Method of using IL-11 for inflammation associated with acute pancreatitis
Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Closbidium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, acute pancreatitis, psoriasis, infertility and allergic disorders such as rhinitis, conjunctivitis, and urticaria.
Owner:GENETICS INST INC
Methods and Åpparatus for Compensating for Retinitis Pigmentosa
ActiveUS20200112691A1Enhance the imageSmall field of viewTelevision system detailsColor television detailsRetinitis pigmentosaComputer science
A system and methods for compensating for retinitis pigmentosa for a user include using a head-mounted and user-controllable device that can minify the image to more closely match the user's reduced field of view. The user may adjust the amount of minification and may also adjust the magnification of the image.
Owner:IRISVISION INC
Traditional Chinese medicine composition for treating central retinitis
InactiveCN104043011AIncrease blood flowFast edema recoverySenses disorderPlant ingredientsSemenAngelica sylvestris
The invention discloses a traditional Chinese medicine composition for treating central retinitis. The traditional Chinese medicine composition is prepared from the following crude drugs in parts by weight: 10-20 parts of barbary wolfberry fruits, 10-20 parts of chrysanthemum, 5-10 parts of loofah sponge, 0 part of glossy privet fruits, 5-10 parts of suberect spatholobus stems, 8-12 parts of semen cassiae, 8-15 parts of cicada slough, 10-20 parts of angelica sinensis, 8-12 parts of angelica sylvestris, 10-20 parts of fructus forsythiae, 8-12 parts of safflowers and 5-10 parts of eclipta alba. The selected crude drugs simultaneously take the effects of dispelling the wind and clearing away heat, promoting blood circulation to remove blood stasis, soothing the liver and dredging collaterals, nourishing yin and dispelling wind, clearing liver and improving vision and the like. Through clinical application, the traditional Chinese medicine composition is found to be rapid in taking effects, high in curative ratio, low in cost, safe and reliable.
Owner:王春水
Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders
ActiveUS10314893B2Good effectAvoid poor resultsPowder deliveryPeptide/protein ingredientsDiseaseUveitis
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Eye ointment for treating eye diseases
InactiveCN102343050AHeat-clearing and detoxifyingAntibacterial and anti-inflammatorySenses disorderAnthropod material medical ingredientsBlurred visionRhizome
The invention discloses an eye ointment for treating eye diseases. The eye ointment is prepared from the following raw materials in parts by weight: chrysanthemum, pen grass, fragrant solomonseal rhizome, mint, divaricate saposhnikovia root, mulberry leaf, amur corktree bark, tabasheer, notopterygium root, goat gall, borneol, coptis root, wild celery, snake gall, dahurian angelica root, heather honey, calculus bovis, fineleaf schizonepeta herb, common anemarrhena, subopposite milkwort herb, wild ginger, Chinese angelica, tea leaf and sesame oil. The entire formula has the effects of clearing away heat and toxic materials, promoting blood circulation to dispel blood stasis, resisting bacteria, reducing inflammation, clearing liver and improving vision, can be used for treating various eye diseases such as puffy eyes, lachrymation, eye dryness and itching, bursting pain, eye white congestion, conjunctivitis, viral conjunctivitis, retinitis, blurred vision and the like, has a simple preparation process, and is fully absorbed by patients.
Owner:贾道忠
New liver and kidney nourishing decoction preparation (novel medicament delivery system) and preparation method thereof
InactiveCN102028861AEnsure extraction efficiencyEnsure non-denaturationAerosol deliveryDigestive systemDiseaseLiver and kidney
The invention discloses a new liver and kidney nourishing decoction preparation (a novel medicament delivery system) for treating hepatitis and a preparation method thereof, which belong to the field of biomedicine. The new preparation comprises six medicinal materials, namely coastal glehnia root, dwarf lilyturf tuber, Chinese angelica, rehmannia root, barbary wolfberry fruit and szechwan Chinaberry fruit, and a proper amount of extract of a coptis component serving as main raw materials, and is prepared by the following steps of: extracting and separating; properly adding medicinal auxiliary materials; and finally preparing by the conventional process of formulations such as sprays, ointments (or syrups), pills, aerosols, dispersible tablets, orally disintegrating tablets, targeting preparations, controlled release preparations and the like. Through improved technology, the curative effect of the conventional compound prescription is further improved, so the technical requirement of controllable quality of the modern Chinese traditional medicine is met, the side effect is also reduced, and the compliance of a clinical medicament is improved. The new preparation has the unique effects of treating difficult and complicated diseases such as the hepatitis, hepatocirrhosis, liver cancer, gastritis, pregnancy-induced hypertension syndrome, tubal ligation syndrome, herpes zoster, central retinitis, recurrent aphtha, other gynecological diseases and the like, so that the new preparation has unique clinical application value.
Owner:周艳
Treatment of retinitis pigmentosa using engineered meganucleases
ActiveUS10603363B2Delay and prevent and reverse progressionDisruptionSenses disorderPeptide/protein ingredientsRetinitis pigmentosaMutant allele
Owner:PRECISION BIOSCI INC
Traditional Chinese medicine composition for treating central retinitis and preparation method thereof
InactiveCN102973745AConform to materialismIn line with dialectical thoughtSenses disorderAnthropod material medical ingredientsCurative effectTwig
The invention discloses a traditional Chinese medicine composition for treating central retinitis, which is prepared from the following raw materials in parts by weight: 10-40 parts of phaseolus calcaratus, 1-16 parts of rhizoma alismatis, 5-25 parts of poria, 1-16 parts of radix stephaniae tetrandrae, 2-22 parts of radix astragali, 5-25 parts of radix salviae miltiorrhizae, 1-20 parts of Chinese angelica, 1-20 parts of rhizoma atractylodis macrocephalae, 5-25 parts of earthworm, 1-20 parts of herba epimedii, 1-20 parts of cassia twig, 8-28 parts of caulis spatholobi and 1-13 parts of liquorice root. The traditional Chinese medicine composition disclosed by the invention has moderate property and good curative effect, and is used for treating central retinitis without laser photocoagulation.
Owner:邢强强
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
ActiveUS20150202269A1Preventing and arresting progressionPreventing and arresting of and vision lossBiocideSenses disorderGene productNucleic acid sequencing
Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Drug combination for treating centrality serous chorioretinitis
InactiveCN101664508ASpeed up edemaPromote absorptionSenses disorderCardiovascular disorderRemove bloodCurative effect
The invention discloses a drug combination for treating centrality serous chorioretinitis, composed of angelica, root of rehmannia, white paeony root, chrysanthemum, the rhizome of chuanxiong, savia miltiorrhiza, tuckahoe, rhizoma polygonati, white caltrop, semen cassiae and pearls. The drug combination has the efficacies of replenishing qi and nourishing blood, clearing heat and cooling blood, promoting blood circulation and removing blood stasis as well as removing nebula and improving eyesight, formula is scientific and curative effect is definite.
Owner:袁宝华 +2
Method of using IL-11 for treating mucositis
Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).
Owner:GENETICS INST INC
Medicinal composition with function of protecting optic nerve and preparation method and application thereof
The invention provides a medicinal composition with the function of protecting optic nerve, which is a preparation prepared by the following raw materials in part by weight: 40 to 400 parts of medlar and 45 to 480 parts of erigeron breviscapus. The medicament is used for treating optic neuropathy caused by liver and kidney deficiency and optic collateral stasis. The research shows that the medicinal composition has the function of protecting optic nerve. The invention is the optic nerve protection medicament for treating retinal diseases mainly comprising normal tension glaucoma, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease.
Owner:成都中医大银海眼科医院股份有限公司
Preparation method of inosine and composition injection thereof
ActiveCN105287370AGuaranteed stabilityEnsure safetyOrganic active ingredientsSenses disorderWhite blood cellOptic nerve atrophy
The invention discloses a preparation method of inosine and a composition injection thereof. The injection is composed of raw materials of inosine and sodium chloride, and accessories of glycine and water for injection. 100ml of the composition contains 0.6 wt% of inosine, 0.9 wt% of sodium chloride and 0.15-0.25wt% of glycine. The injection is a large volume injection prepared from inosine and pharmaceutically acceptable accessories and has stable quality; and the injection is used for auxiliary treatment of leukopenia, thrombocytopenia, heart failure, angina pectoris and hepatitis caused by various reasons, and can also be used for auxiliary treatment of optic atrophy and central retinitis. The invention also involves preparation of a composition injection containing polygeline and inosine; the composition injection is a large volume injection prepared from polygeline, inosine and pharmaceutically acceptable excipients and has stable quality; and the composition injection is used for acute normovolemic hemodilution, improves microcirculation and prevents the occurrence of ischemic and hypoxic injury of tissues.
Owner:FUZHOU NEPTUNUS FUYAO PHARMA
Methods of treating retinitis pigmentosa
Owner:MIMETOGEN PHARMA
Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
InactiveUS20100056623A1Excellent angiogenesis-inhibiting effectOrganic active ingredientsBiocideSolubilityDepressant
The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt or inclusion compound. The present invention provides fumagillol derivatives having the following characteristics: increased inhibiting effect on angiogenesis, low toxicity, excellent solubility and chemical stability as compared to conventional angiogenesis inhibitors. The compounds of the present invention can be used as an anti-cancer medicine, inhibitor of cancer metastasis, or the therapeutic agent for treating rheumatic arthritis, psoriasis, diabetic retinitis or obesity.
Owner:CHONG KUN DANG PHARMA CORP
Methods of Treating Ocular Disorders
InactiveUS20200093852A1Organic active ingredientsSenses disorderRetinitis pigmentosaOcular inflammation
This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.
Owner:BETA THERAPEUTICS PTY LTD
Use of steroid compounds for inflammatory and autoimmune disorders
This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammatory conditions, including, but not limited to asthma, lung inflammation, retinal inflammatory conditions, autoimmune diseases such as rheumatoid arthritis, diabetes type I, systemic lupus erythematosus, ulcerative colitis and inflammatory bowel diseases and myopathies, as well as multiple sclerosis. The active compounds are represented by Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, B, X, Y and Z are defined in the description of the invention.
Owner:BIONATURE E A LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com